January 31, 2026 · Form 4 insider transaction
Boyer David W. bought 2,096 shares of Neurocrine Biosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 3 days after the transaction.
Includes an aggregate of 241 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.